Counterpoints: Which should be used first in symptomatic metastatic castration-resistant prostate cancer, docetaxel or radium? Docetaxel still the optimal first choice for symptomatic metastatic castration-resistant prostate cancer.
University of Virginia Cancer Center, Charlottesville, Virginia.
Robert
R
Dreicer
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001918:Brachytherapy / Q000009:adverse effects; D000066491:Clinical Decision-Making; D000077143:Docetaxel; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D010146:Pain / Q000209:etiology; D010147:Pain Measurement; D064129:Prostatic Neoplasms, Castration-Resistant / Q000150:complications / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D011788:Quality of Life; D011883:Radium / Q000009:adverse effects / Q000627:therapeutic use*; D043823:Taxoids / Q000009:adverse effects / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D043823:Taxoids; D000077143:Docetaxel; D011883:Radium